Phase II study of capecitabine (C) in combination with docetaxel (D) as neoadjuvant treatment in patients with locally advanced breast cancer (IIIA and IIIB stage). Correlation between clinico-pathological response and fluoropyrimidine-enzyme profile. Early results | Publicación